TERMIS 2021 | Clinical translation of biomaterials
May Griffith, PhD, University of Montreal & Hopital Maisonneuve-Rosemont, Montreal, Canada, provides an overview of designing biomaterials for clinical trials and problems associated with the process. Prof. Griffith emphasizes the need for long-term planning and careful consideration of multiple variables including scalability and safety for successful authorization by regulatory authorities. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).
Disclosures
Prof. Griffith is a named inventor on PCT patents WO2007/028258 A2 Interpenetrating networks, and related methods and compositions, assigned to the Ottawa Hospital Research Institute and University of Ottawa; PCT/IB2017/056342 Collagen and CLP-based hydrogels, corneal implants, filler glue and uses thereof, which was assigned to the Hyderabad Eye Research Foundation, and then subsequently assigned to North Grove Investments, Inc. wherein PCT national phase applications have been filed in the USA, EU, India, China, and Canada. She is also a named inventors on a US provisional patent application no. 62916765, subsequent to a disclosure to Maisonneuve-Rosemont Hospital and Université de Montréal.
